Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B‐cell lymphoma. Issue 11 (11th February 2015)

• Record Type: Journal Article
• Authors: Williams, Jessica N.; Rai, Ashish; Lipscomb, Joseph; Koff, Jean L.; Nastoupil, Loretta J.; Flowers, Christopher R.
• Is Part Of: Cancer. Volume 121:Issue 11(2015)
• Page Start: 1800
• Page End: 1808
• Publication Date: 2015-02-11
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29290
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29290-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) is considered standard therapy for diffuse large B‐cell lymphoma (DLBCL), patterns of use and the impact of R‐CHOP on survival in patients aged >80 years are less clear.</p> </sec> <sec id="cncr29290-sec-0002" sec-type="section"> <title>METHODS</title> <p>The Surveillance, Epidemiology, and End Results (SEER)‐Medicare database was used to characterize presentation, treatment, and survival patterns in patients with DLBCL who were diagnosed between 2002 and 2009. Chi‐square tests compared characteristics and initial treatments among patients with DLBCL who were aged >80 years and ≤80 years. Multivariable logistic regression models examined factors associated with treatment selection in patients aged >80 years; standard and propensity score‐adjusted multivariable Cox proportional hazards models examined relationships between treatment regimen, treatment duration, and survival.</p> </sec> <sec id="cncr29290-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Among 4635 patients with DLBCL, 1156 (25%) were aged >80 years. Patients aged >80 years were less likely to receive R‐CHOP and more likely to be observed or receive the combination of rituximab, cyclophosphamide, vincristine, and prednisone (<italic>P</italic><.0001 for both). Marital status, stage of disease, disease site, performance status, radiotherapy, and growth factor support were associated with initial R‐CHOP in patients aged >80 years. In propensity score‐matched multivariable Cox proportional hazards models examining relationships between treatment regimen and survival, R‐CHOP was the only regimen found to be associated with improved overall survival (hazard ratio, 0.45; 95% confidence interval, 0.33‐0.62) and lymphoma‐related survival (hazard ratio, 0.58; 95% confidence interval, 0.38‐0.88).</p> </sec> <sec id="cncr29290-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Although patients with DLBCL who were aged >80 years were less likely to receive R‐CHOP, this regimen conferred the longest survival and should be considered for this population. Further studies are needed to characterize the impact of treatment of DLBCL on quality of life among patients in this age group. <bold><italic>Cancer</italic> 2015;121:1800–1808.</bold> © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>